This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Accelerates Cancer-Immunotherapy Program With Three Collaborations

By: Adam Feuerstein | 02/05/14 - 07:48 AM EST

Merck (MRK) is throwing a cancer-immunotherapy party and has invited several friends. 

In three separate collaboration agreements announced Wednesday, Merck is planning clinical trials to combine its anti-PD-1 immunotherapy MK-3475 with complimentary anti-cancer compounds owned by Amgen (AMGN), Incyte (INCY) and Pfizer (PFE). Financial terms of the agreements were not disclosed. 

The new collaborations are significant because they help Merck close the competitive gap with Bristol-Myers Squibb (BMY), which is largely viewed as the front runner in the race to develop the new class of anti-PD-1 immunotherapies, which work by releasing a brake on the patient's immune system to better recognize and kill tumors. 

Bristol has been developing its anti-PD-1 nivolumumab as a monotherapy and in combination with other drugs, including Yervoy. Merck is now mimicking that playbook, studying MK-3475 (also known as lambrolizumab) and in combination therapy. 

"Merck clinical scientists intend to explore the potential of our PD-1 inhibitor across a wide range of cancers, both as monotherapy and in combination," said Roger Perlmutter, Merck's top scientist in charge of R&D. "These new collaborations with Amgen, Incyte and Pfizer underscore our shared determination to evaluate treatment regimens with the potential to provide meaningful benefits to patients suffering from cancer."

The collaboration between Merck and Amgen is a homecoming of sorts for Perlmutter, who used to run Amgen's drug development operations. Merck will study MK-3475 in combination with Amgen's oncolytic vaccine T-Vec in a phase I/II study in patients with previously untreated advanced melanoma. Perlmutter was responsible for bringing T-Vec into Amgen through an acquisition, so it's a therapy he knows well.

Merck will also be collaborating with Incyte to combine MK-3475 with INCB24360, a so-called "IDO inhibitor," in a study of patients with non-small cell lung cancer and other metastatic cancers. 

Finally, Merck plans to evaluate MK-3474 with two Pfizer drugs -- Inlyta and PF-2566 -- in kidney and other cancers. 

"Merck now seems to get that the PD-1 cancer race is hyper-hyper-hyper competitive, and as such, now seems to be picking up the pace of its announcements," writes ISI Group analyst Mark Schoenebaum in an email to investor clients this morning. 

Earlier this month, Merck surprised investors by announcing that MK-3475 would be filed for approval with the FDA sooner than expected for skin cancer patients who no longer respond to Bristol's Yervoy. 

Of the three collaborations announced today, Schoenebaum points to the combination with Incyte's INCB24360 as the most significant because IDO inhibitors have "generated significant buzz among investors and doctors as a promising immuno-oncology approach that could be complimentary to PD-1."




Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Get More Investment Ideas:

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,051.73 -48.45 -0.28%
S&P 500 1,973.63 -4.59 -0.23%
NASDAQ 4,424.7040 -7.4420 -0.17%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs